Expert review of respiratory medicine最新文献_第8页

Interstitial lung diseases: never forget to think about it in primary care. 间质性肺病：在初级保健中不要忘记考虑它。

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2024-03-19 DOI: 10.1080/17476348.2024.2331763

Guadalupe Bermudo, Miguel Roman-Rodriguez, Maria Molina-Molina

引用次数: 0

Correction. 更正。

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2023-12-20 DOI: 10.1080/17476348.2023.2295593

引用次数: 0

Drug-induced interstitial lung disease: a narrative review of a clinical conundrum. 药物诱发的间质性肺病：临床难题的叙述性回顾。

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2024-03-19 DOI: 10.1080/17476348.2024.2329612

Megan Harrison, Grace Kavanagh, Tamera J Corte, Lauren K Troy

{"title":"Drug-induced interstitial lung disease: a narrative review of a clinical conundrum.","authors":"Megan Harrison, Grace Kavanagh, Tamera J Corte, Lauren K Troy","doi":"10.1080/17476348.2024.2329612","DOIUrl":"10.1080/17476348.2024.2329612","url":null,"abstract":"Introduction: Drug-induced interstitial lung disease (DI-ILD) is increasing in incidence, due to the use of many new drugs across a broad range of cancers and chronic inflammatory diseases. The presentation and onset of DI-ILD are variable even for the same drug across different individuals. Clinical suspicion is essential for identifying these conditions, with timely drug cessation an important determinant of outcomes.Areas covered: This review provides a comprehensive and up-to-date summary of epidemiology, risk factors, pathogenesis, diagnosis, treatment, and prognosis of DI-ILD. Relevant research articles from PubMed and Medline searches up to September 2023 were screened and summarized. Specific drugs including immune checkpoint inhibitors, CAR-T cell therapy, methotrexate, and amiodarone are discussed in detail. The potential role of pharmacogenomic profiling for lung toxicity risk is considered.Expert opinion: DI-ILD is likely to be an increasingly important contributor to respiratory disability in the community. These conditions can negatively impact quality of life and patient longevity, due to associated respiratory compromise as well as cessation of evidence-based therapy for the underlying disease. This clinical conundrum is relevant to all areas of medicine, necessitating increased understanding and greater vigilance for drug-related lung toxicity.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"23-39"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

So we now have RSV vaccines. What's our next steps? 现在我们有了 RSV 疫苗。下一步该怎么办？

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2024-03-19 DOI: 10.1080/17476348.2024.2331764

Joseph M Blondeau

引用次数: 0

Factors associated with anxiety and depression among patients with chronic obstructive pulmonary disease. 慢性阻塞性肺病患者焦虑和抑郁的相关因素。

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2024-03-07 DOI: 10.1080/17476348.2024.2326512

Anan S Jarab, Walid A AlQerem, Shrouq R Abu Heshmeh, Yazid N Al Hamarneh, Salah Aburuz, Judith Eberhardt

{"title":"Factors associated with anxiety and depression among patients with chronic obstructive pulmonary disease.","authors":"Anan S Jarab, Walid A AlQerem, Shrouq R Abu Heshmeh, Yazid N Al Hamarneh, Salah Aburuz, Judith Eberhardt","doi":"10.1080/17476348.2024.2326512","DOIUrl":"10.1080/17476348.2024.2326512","url":null,"abstract":"Objectives: This study investigated factors associated with anxiety and depression in COPD outpatients.Methods: A cross-sectional study of 702 COPD outpatients from two major Jordanian hospitals using the Hospital Anxiety and Depression Scale (HADS) was conducted.Results: Significant associations were found with gender (Anxiety OR: 5.29, 95%CI: 2.38-11.74; Depression OR: 0.20, 95%CI: 0.08-0.51), disease severity (Anxiety OR: 2.97, 95%CI: 1.80-4.91; Depression OR: 15.95, 95%CI: 5.32-52.63), LABA use (Anxiety OR: 16.12, 95%CI: 8.26-32.26; Depression OR: 16.95, 95%CI: 8.33-34.48), medication count (Anxiety OR: 0.73, 95%CI: 0.59-0.90; Depression OR: 0.51, 95%CI: 0.40-0.64), mMRC score (Anxiety OR: 2.41, 95%CI: 1.81-3.22; Depression OR: 2.31, 95%CI: 1.76-3.03), and inhalation technique (Anxiety OR: 0.95, 95%CI: 0.93-0.97; Depression OR: 0.92, 95%CI: 0.90-0.95). Other factors associated with anxiety included high income, urban living, diabetes, hypertension, LAMA use, and fewer COPD medications. Depression was also linked with heart disease, increased age, and longer disease duration.Conclusion: The prevalence of anxiety and depression among COPD patients necessitates targeted interventions. Future research that recruits a more diverse sample in multiple sites and establishes the cause-effect relationship between the study predictors and outcome could provide a more robust conclusion on factors associated with anxiety and depression among COPD patients.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"59-65"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140061598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do all patients with cancer thrombosis have the same risk of bleeding and recurrence? Particularities of lung cancer. 是否所有癌症血栓患者都有同样的出血和复发风险？肺癌的特殊性。

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2024-03-18 DOI: 10.1080/17476348.2024.2331750

Laurent Bertoletti, Ludovic Lafaie, Thibault LeConte, Anne-Laure Desage, Bastien Petit, Lutfi Ozturk, Sandrine Accassat, Pauline Corbaux, Géraldine Poenou

引用次数: 0

Diversity in pulmonary rehabilitation clinical trials: a systematic review of the literature. 肺康复临床试验的多样性：文献系统回顾。

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2024-03-06 DOI: 10.1080/17476348.2024.2324086

Sunaina Chopra, Shivani Rana, Reenal Patel, Tessa Hamilton, Alyssa Dalip, Paramvir Malhi, Pat G Camp

{"title":"Diversity in pulmonary rehabilitation clinical trials: a systematic review of the literature.","authors":"Sunaina Chopra, Shivani Rana, Reenal Patel, Tessa Hamilton, Alyssa Dalip, Paramvir Malhi, Pat G Camp","doi":"10.1080/17476348.2024.2324086","DOIUrl":"10.1080/17476348.2024.2324086","url":null,"abstract":"Background: Underrepresentation of minority groups in clinical trials may hinder the potential benefits of pulmonary rehabilitation (PR) programs for individuals with chronic obstructive pulmonary disease (COPD). The aim of this work was to determine whether participants in PR randomized control trials (RCTs) conducted in the U.S.A., Canada, the UK, and Australia are representative of ethnicity, sex, gender, and sociodemographic characteristics.Research design: A systematic search was performed for relevant literature from inception to December 2022. Titles and abstracts were screened before undergoing a full article review. Relevant data on reporting of age, sex, gender, ethnicity, and sociodemographic characteristics of participants was extracted.Results: Thirty-six RCTs met the inclusion criteria. Only 6% of publications reported on ethnicity, with ≥90% of participants reported as 'White.' All 36 papers reported on age, with the mean between 60 and 69 years old. Thirty-five studies reported on sex (97%), with the majority (67%) reporting more male than female participants. There was no mention of different genders in any paper. Other sociodemographic factors were reported in 7 (19%) papers.Conclusions: Inclusivity and representation in clinical trials are essential to ensure that research findings are generalizable. Clinical trialists need to consider the demographics of today's society during recruitment.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"49-58"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypercapnia and its relationship with respiratory infections. 高碳酸血症及其与呼吸道感染的关系。

Expert review of respiratory medicine Pub Date : 2024-01-01 Epub Date: 2024-03-19 DOI: 10.1080/17476348.2024.2331767

Elena Campaña-Duel, Adrian Ceccato, Luis Morales-Quinteros, Marta Camprubí-Rimblas, Antonio Artigas

{"title":"Hypercapnia and its relationship with respiratory infections.","authors":"Elena Campaña-Duel, Adrian Ceccato, Luis Morales-Quinteros, Marta Camprubí-Rimblas, Antonio Artigas","doi":"10.1080/17476348.2024.2331767","DOIUrl":"10.1080/17476348.2024.2331767","url":null,"abstract":"Introduction: Hypercapnia is developed in patients with acute and/or chronic respiratory conditions. Clinical data concerning hypercapnia and respiratory infections interaction is limited.Areas covered: Currently, the relationship between hypercapnia and respiratory infections remains unclear. In this review, we summarize studies on the effects of hypercapnia on models of pulmonary infections to clarify the role of elevated CO2 in these pulmonary pathologies. Hypercapnia affects different cell types in the alveoli, leading to changes in the immune response. In vitro studies show that hypercapnia downregulates the NF-κβ pathway, reduces inflammation and impairs epithelial wound healing. While in vivo models show a dual role between short- and long-term effects of hypercapnia on lung infection. However, it is still controversial whether the effects observed under hypercapnia are pH dependent or not.Expert opinion: The role of hypercapnia is still a controversial debate. Hypercapnia could play a beneficial role in mechanically ventilated models, by lowering the inflammation produced by the stretch condition. But it could be detrimental in infectious scenarios, causing phagocyte dysfunction and lack of infection control. Further data concerning hypercapnia on respiratory infections is needed to elucidate this interaction.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"41-47"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indications and evidence for domiciliary noninvasive ventilation. 家用无创通气的适应症和证据。

Expert review of respiratory medicine Pub Date : 2023-12-01 Epub Date: 2023-12-27 DOI: 10.1080/17476348.2023.2295941

Anita Saigal, Amar J Shah, Swapna Mandal

{"title":"Indications and evidence for domiciliary noninvasive ventilation.","authors":"Anita Saigal, Amar J Shah, Swapna Mandal","doi":"10.1080/17476348.2023.2295941","DOIUrl":"10.1080/17476348.2023.2295941","url":null,"abstract":"Introduction: Home noninvasive ventilation (HNIV) has expanded globally, with a greater evidence base for its use. HNIV improves multiple patient related outcomes in patients with chronic hypercapnic respiratory failure. Obesity hypoventilation syndrome (OHS) is rapidly taking over as the primary indication for HNIV and COPD patients who overlap with obstructive sleep apnea hypoventilation syndromes (OSAHS) and are increasingly recognized but add to the complexity of HNIV prescribing. Optimal settings vary for differing diseases, with higher inspiratory pressures often required in those with OHS and COPD, yet which settings translate into greatest patient benefit remains unknown.Areas covered: We cover the evidence base underpinning the common indications for HNIV in COPD, OHS, neuromuscular disease (NMD), and chest wall disease (CWD) and highlight common HNIV modes used.Expert opinion: Active screening for nocturnal hypoventilation in OHS and COPD may be important to guide earlier ventilation. Further research on which HNIV modalities best improve patient related outcomes and the right time for initiation in different patient phenotypes is rapidly needed. Worldwide, clinical research trials should aim to bridge the gap by reporting on patient-related outcomes and cost effectiveness in real-world populations to best understand the true benefit of HNIV amongst heterogenous patient populations.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1141-1150"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First-line immunotherapy in non-small cell lung cancer: how to select and where to go. 非小细胞肺癌的一线免疫疗法：如何选择，何去何从？

Expert review of respiratory medicine Pub Date : 2023-12-01 Epub Date: 2024-02-09 DOI: 10.1080/17476348.2024.2302356

Andrea Mogavero, Ornella Cantale, Veronica Mollica, Shobana Anpalakhan, Alfredo Addeo, Giannis Mountzios, Alex Friedlaender, Ravindran Kanesvaran, Silvia Novello, Giuseppe Luigi Banna

{"title":"First-line immunotherapy in non-small cell lung cancer: how to select and where to go.","authors":"Andrea Mogavero, Ornella Cantale, Veronica Mollica, Shobana Anpalakhan, Alfredo Addeo, Giannis Mountzios, Alex Friedlaender, Ravindran Kanesvaran, Silvia Novello, Giuseppe Luigi Banna","doi":"10.1080/17476348.2024.2302356","DOIUrl":"10.1080/17476348.2024.2302356","url":null,"abstract":"Introduction: Immunotherapy (IO) has established a new milestone in lung cancer treatment. Several registrational studies have approved immune checkpoint inhibitors (ICIs) in different settings, including the metastatic nonsmall cell lung cancer (NSCLC). As well known, responders are just a certain proportion of patients; therefore, their selection by using predictive factors has stood out as a crucial issue to address in tailoring a patient-centered care.Areas covered: In our review we propose a detailed yet handy cross section on ICIs as first-line treatment in metastatic NSCLC, regarding indications, histological, clinical, and blood-based biomarkers, other than their mechanisms of resistance and new immunological actionable targets. We performed a literature search through PubMed entering keywords complying with crucial features of immunotherapy.Expert opinion: IO represents the backbone of lung cancer treatment. Trials are currently testing novel immune blockade agents assessing combinatorial approaches with standard ICIs, or antibody drug conjugates (ADC), harboring immunological targets. Perfecting patients' selection is an ongoing challenge and a more and more urgent need in order to best predict responders who will consistently benefit from it.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1191-1206"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0